$0.25 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP)

October 16, 2017 - By Clifton Ray

 $0.25 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP)
Investors sentiment decreased to 1.33 in Q2 2017. Its down 0.06, from 1.39 in 2017Q1. It dropped, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.
27,200 are held by Ellington Mngmt Gru Lc. Dekabank Deutsche Girozentrale invested in 0% or 11,100 shares. Bowling Management Ltd owns 135,021 shares. Prudential Fincl invested in 42,233 shares or 0% of the stock. Sei Invests, a Pennsylvania-based fund reported 4,965 shares. The New Jersey-based Palisade Capital Limited Liability Nj has invested 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tfs Cap Limited Company has 83,694 shares for 0.34% of their portfolio. Intrust Bank & Trust Na has 0.06% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Wellington Management Group Limited Liability Partnership holds 78,864 shares. Bnp Paribas Arbitrage Sa accumulated 25,294 shares. Affinity Investment Advsr Limited Liability Corp accumulated 0.03% or 22,199 shares. Ny State Common Retirement Fund reported 34,970 shares or 0% of all its holdings. First Trust Advsr L P has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Price T Rowe Associate Md owns 10,473 shares. Herndon Capital Mgmt Ltd Liability has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Wall Street await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to release earnings on November, 8. Analysts forecast earnings per share of $0.25, down exactly $0.03 or 10.71 % from 2014’s $0.28 EPS. The expected SCMP’s profit could reach $11.64M giving the stock 10.20 P/E in the case that $0.25 earnings per share is reported. After posting $0.28 EPS for the previous quarter, Sucampo Pharmaceuticals, Inc.’s analysts now forecast -10.71 % negative EPS growth. The stock decreased 1.92% or $0.2 on October 13, reaching $10.2. About 513,824 shares traded. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since October 16, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Sucampo Pharma had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 26 by Maxim Group. Jefferies maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Wednesday, March 9. Jefferies has “Hold” rating and $16 target. The firm has “Buy” rating by UBS given on Tuesday, February 9. The firm has “Buy” rating given on Wednesday, August 2 by Maxim Group. The firm earned “Hold” rating on Thursday, August 27 by WallachBeth Capital. Roth Capital reinitiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Thursday, October 29. Roth Capital has “Buy” rating and $29 target. The stock has “Hold” rating by WallachBeth Capital on Thursday, August 6. The firm has “Buy” rating given on Thursday, October 12 by UBS. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Friday, November 20 by Jefferies. Mizuho maintained the shares of SCMP in report on Monday, November 14 with “Neutral” rating.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $474.84 million. The Firm is focused on the development and commercialization of pharmaceutical products. It currently has negative earnings. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

More notable recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Seekingalpha.com which released: “Sucampo Firing Sales Torpedos” on September 07, 2017, also Globenewswire.com with their article: “Sucampo Acquires Vtesse Inc.” published on April 03, 2017, Seekingalpha.com published: “Sucampo: A Shift Toward Rare Diseases” on July 27, 2017. More interesting news about Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) were released by: Globenewswire.com and their article: “Dr. Karen Smith Joins Sucampo’s Board of Directors” published on July 18, 2017 as well as Bizjournals.com‘s news article titled: “Md. biotech expands HQ in ramp-up for potential drug approval” with publication date: September 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com